Dapoxetine (Priligy) for Premature Ejaculation: Dosing, Effectiveness, and How It Compares to ED Drugs

What is dapoxetine and how does it work?

Dapoxetine is a short-acting SSRI specifically engineered for on-demand use rather than daily dosing. It inhibits the serotonin transporter, raising synaptic serotonin at spinal ejaculatory centers, which extends the time to ejaculation. Its rapid absorption (T-max roughly 1 hour) and short half-life (1.5 to 2 hours for the parent compound) make it practical to take only before planned sexual activity, unlike daily antidepressants such as paroxetine that require weeks of loading [1].

The pharmacology is distinct from phosphodiesterase type 5 (PDE5) inhibitors used for erectile dysfunction. PDE5 inhibitors increase cyclic guanosine monophosphate in penile smooth muscle, relaxing trabecular tissue to allow blood inflow. Dapoxetine does not act on this pathway at all. A man with premature ejaculation (PE) and no erectile difficulty needs dapoxetine, not a PDE5 inhibitor. A man with both conditions may benefit from combination therapy, discussed below [2].

Premature ejaculation affects an estimated 20 to 30 percent of men across age groups according to the American Urological Association's guideline update [3]. The International Society of Sexual Medicine defines lifelong PE as an ejaculatory latency of less than one minute in the majority of intercourse attempts [4]. Without pharmacological support, behavioral strategies alone often produce modest and poorly maintained improvements.

Clinical trial data: what the phase-III evidence actually shows

The PRILIGY phase-III program enrolled 6,081 men with PE across five randomized controlled trials and measured intravaginal ejaculatory latency time (IELT) using a partner-held stopwatch. Baseline IELT was less than 2 minutes for all participants.

At 24 weeks, dapoxetine 30 mg increased geometric mean IELT from 0.9 minutes at baseline to 1.9 minutes (2.1-fold increase), and dapoxetine 60 mg increased it to 2.8 minutes (3.1-fold increase), compared with 1.5 minutes on placebo (1.7-fold increase) [5]. The difference between both active doses and placebo was statistically significant (P<0.001).

Patient-reported outcome data from the same program showed that the premature ejaculation profile (PEP) "control over ejaculation" domain improved by 49 percent with 30 mg and 58 percent with 60 mg versus 29 percent for placebo [5]. The Clinical Global Impression of Change score showed "much" or "very much" improved ratings in 64.8 percent of dapoxetine 60 mg patients versus 39.3 percent of placebo patients.

A 2022 Cochrane systematic review of SSRIs and other pharmacological agents for PE (Kirby et al.) confirmed that dapoxetine produced consistent IELT prolongation across studies and noted its favorable safety profile compared with daily SSRI use, citing lower rates of sexual side effects such as anorgasmia [6].

One phase-III trial arm also randomized 1,067 men to the combination of dapoxetine 60 mg plus tadalafil 20 mg when comorbid erectile dysfunction was present. IELT improvement was comparable to dapoxetine alone, and erectile function scores (IIEF-EF domain) improved by a mean of 8.2 points from baseline, a clinically meaningful change per the threshold of 4 points established in IIEF validation studies [7].

Dosing and administration

The starting dose is 30 mg taken orally 1 to 3 hours before anticipated sexual activity. If 30 mg is tolerated but the ejaculatory delay is insufficient, the dose may be increased to 60 mg. Only one dose is permitted per 24-hour period [8].

Dapoxetine should be taken with a full glass of water. Food does not significantly alter peak plasma concentration but may delay T-max by approximately 30 minutes, so taking it with a heavy meal just before sex could slightly blunt the onset. Alcohol should be avoided because the combination increases the risk of vasovagal syncope and orthostatic hypotension [8].

Dose adjustments apply in specific groups. Men with mild-to-moderate hepatic impairment (Child-Pugh A or B) should not exceed 30 mg. The drug is contraindicated in severe hepatic impairment (Child-Pugh C). No renal dose adjustment is required for creatinine clearance above 30 mL/min, but the manufacturer advises caution below that threshold [9].

Monoamine oxidase inhibitors are an absolute contraindication. A 14-day washout period is required after stopping an MAOI before starting dapoxetine. Strong CYP3A4 inhibitors such as ketoconazole, ritonavir, and clarithromycin substantially raise dapoxetine plasma levels and are also contraindicated [9].

Safety profile and side effects

The most common adverse events across the pooled phase-III data were nausea (8.7 percent with 30 mg, 20.1 percent with 60 mg versus 3.1 percent placebo), dizziness (5.8 percent and 10.9 percent versus 2.1 percent), and headache (5.9 percent and 8.8 percent versus 4.0 percent) [5].

Syncope occurred in approximately 0.1 percent of men across the program, typically within 3 hours of dosing. Patients are advised to sit or lie down if they feel faint. This risk is one reason dapoxetine carries a precaution about driving or operating machinery within 12 hours of the dose.

Discontinuation due to adverse events was 4 percent for the 30 mg group and 8.8 percent for the 60 mg group, versus 1.6 percent for placebo [5]. The rate of sexual dysfunction side effects such as ejaculatory failure or anorgasmia was below 1 percent, meaningfully lower than what is reported with daily paroxetine (3 to 12 percent across trials) [6].

Suicide ideation, a class warning for all SSRIs in some jurisdictions, has not been observed at rates above placebo in dapoxetine trials, likely because its short half-life prevents sustained central serotonin loading. Still, prescribers in countries following EU Summary of Product Characteristics guidelines screen patients with a prior history of mania, bipolar disorder, or active suicidal ideation before prescribing [8].

Dapoxetine vs. sildenafil (Viagra): different problems, different drugs

Sildenafil (Viagra) was approved by the FDA in March 1998 for erectile dysfunction at doses of 25 mg, 50 mg, and 100 mg taken 30 to 60 minutes before intercourse [10]. It inhibits PDE5, the enzyme that degrades cyclic GMP in penile smooth muscle. The result is vasodilation and improved erectile response to sexual stimulation.

Sildenafil does not delay ejaculation in men with normal erectile function. A 2020 meta-analysis in the Journal of Sexual Medicine (Xu et al., 14 RCTs, N=1,423) found that sildenafil alone did not significantly extend IELT compared with placebo in men without ED, though it improved erectile confidence in men with performance anxiety who experienced early ejaculation secondary to rushing [11].

When a man has both PE and ED, the combination of dapoxetine 60 mg and sildenafil 50 mg has been studied. A randomized trial by Althof et al. (N=284) showed significantly greater improvement in both IELT (3.6-fold versus 1.9-fold for sildenafil monotherapy) and IIEF erectile function domain scores compared with either agent alone [12].

The practical take: if PE is the primary complaint and erections are satisfactory, choose dapoxetine. If ED is primary and erections are insufficient, start with sildenafil or another PDE5 inhibitor. If both conditions are present, a combination under physician supervision is evidence-supported.

Dapoxetine vs. tadalafil (Cialis): the long-acting PDE5 inhibitor

Tadalafil (Cialis) is approved for ED at 10 mg or 20 mg as needed or 2.5 mg to 5 mg once daily, and separately for benign prostatic hyperplasia at 5 mg daily [13]. Its half-life of approximately 17.5 hours underlies the common "36-hour" marketing claim and allows more flexibility in timing compared with sildenafil.

Like sildenafil, tadalafil has no direct ejaculatory delay mechanism. A 2017 RCT published in the Asian Journal of Andrology (Bai et al., N=90) compared tadalafil 5 mg daily versus dapoxetine 30 mg on-demand versus combination therapy over 12 weeks. Geometric mean IELT rose from 58 seconds at baseline to 99 seconds with tadalafil alone, 178 seconds with dapoxetine alone, and 247 seconds with combination therapy [14]. Dapoxetine produced a meaningfully larger ejaculatory delay on its own.

Daily tadalafil is a reasonable choice when a patient has both ED and lower urinary tract symptoms from BPH, since it addresses both conditions with a single pill. Adding dapoxetine for concurrent PE is clinically reasonable and does not create pharmacokinetic interactions of clinical significance [9].

Dapoxetine vs. vardenafil (Levitra, Staxyn): head-to-head context

Vardenafil (Levitra) was FDA-approved in 2003 for ED at doses of 5, 10, and 20 mg [15]. Its PDE5 selectivity profile is similar to sildenafil, with a T-max of 30 to 120 minutes and duration of action of 4 to 6 hours. Staxyn is an orally disintegrating formulation of vardenafil 10 mg.

No large-scale direct head-to-head RCT comparing vardenafil monotherapy with dapoxetine for PE has been published as of this writing. A small crossover study by Atan et al. (N=30) reported modest IELT increases with vardenafil 20 mg in men with PE, but the absolute values remained below those seen with dapoxetine 30 mg in the phase-III program [16]. Vardenafil's mechanism does not target the ejaculatory reflex arc.

For men who find sildenafil produces visual side effects (blue-tinge disturbance from PDE6 cross-inhibition) or back pain associated with tadalafil (myalgia is reported in 5 to 10 percent of tadalafil users), vardenafil is a reasonable alternative PDE5 inhibitor for the ED component. Dapoxetine remains the pharmacologically appropriate agent for the PE component regardless of which PDE5 inhibitor is chosen.

Dapoxetine vs. avanafil (Stendra): the fastest-onset PDE5 inhibitor

Avanafil (Stendra) was FDA-approved in 2012 for ED at doses of 50, 100, and 200 mg, with a labeled onset as fast as 15 minutes at the 200 mg dose [17]. Its high PDE5 selectivity over PDE6 and PDE11 reduces the rates of visual disturbance and myalgia compared with older PDE5 inhibitors, making it well-tolerated in men who experienced those side effects on sildenafil or tadalafil.

The REVIVE trial (N=440) showed that avanafil 100 mg and 200 mg enabled successful intercourse attempts in 57 percent and 59 percent of attempts versus 27 percent for placebo at 12 weeks, with onset within 15 minutes for approximately 64 percent of successful attempts at the 200 mg dose [18].

Avanafil, like all PDE5 inhibitors, has no established role in treating PE in the absence of ED. A man asking for the fastest-acting sexual medication and whose problem is ejaculation speed rather than erection quality will not find the answer in avanafil. Dapoxetine remains the only pharmacological agent specifically designed and approved for on-demand PE management.

Selecting the right drug: a clinical decision framework

Choosing among these agents depends on identifying which problem the patient actually has.

Step 1: Define the primary complaint. PE without ED points directly to dapoxetine. ED without PE points to a PDE5 inhibitor selected based on desired duration, side-effect profile, and dosing preference. Both PE and ED together support combination therapy.

Step 2: Select the PDE5 inhibitor for ED based on patient-specific factors. Sildenafil 50 mg is appropriate when the patient wants a well-studied, low-cost option and can plan 30 to 60 minutes ahead. Tadalafil 5 mg daily suits men who prefer spontaneity or who also have BPH symptoms. Vardenafil 10 mg or 20 mg is reasonable when sildenafil produces visual side effects. Avanafil 100 to 200 mg fits men who need the shortest onset window or who cannot tolerate myalgia from tadalafil.

Step 3: Verify contraindications before prescribing dapoxetine. Screen for MAOI use, strong CYP3A4 inhibitors, history of syncope, severe hepatic impairment, and active mania or suicidal ideation. Orthostatic hypotension screening (standing blood pressure drop of more than 20 mmHg systolic) should be performed before initiating any combination with a nitrate-free PDE5 inhibitor.

Step 4: Start low, reassess at 4 weeks. Begin dapoxetine at 30 mg and allow at least 5 to 6 sexual encounters before escalating to 60 mg. A PEP questionnaire at the 4-week visit captures control, distress, satisfaction, and interpersonal difficulty across four validated domains to quantify response [4].

According to the European Association of Urology (EAU) 2023 Guidelines on Sexual and Reproductive Health: "Dapoxetine is the only drug specifically developed for on-demand treatment of PE and has the highest level of evidence (Grade A recommendation) for pharmacological management of lifelong and acquired PE" [19].

Behavioral therapies alongside dapoxetine

Pharmacotherapy produces better outcomes when combined with behavioral techniques. The stop-start method (Semans technique) and the squeeze technique (Masters and Johnson) have evidence from small RCTs showing IELT improvements of 30 to 60 seconds on their own [20]. When these are added to dapoxetine, the durability of ejaculatory control after eventual drug discontinuation is improved, as neural conditioning during extended latency supports long-term habituation.

Pelvic floor muscle training is a third option. A 2014 RCT by Pastore et al. (N=40) found that 12 weeks of pelvic floor rehabilitation produced a mean IELT increase from 31.7 seconds to 146.2 seconds, a result comparable to pharmacotherapy [21]. Combining pelvic floor training with dapoxetine has not been studied in a large RCT, but the mechanistic rationale for additive benefit is plausible.

Psychosexual counseling addressing performance anxiety, partner communication, and sexual self-confidence addresses dimensions that medication cannot reach. A prescribing plan that includes a referral to a sex therapist or certified counselor when distress is high increases the probability of sustained improvement beyond the medication period.

Obtaining dapoxetine outside the United States

Since dapoxetine is not FDA-approved, US patients have two legal pathways. First, some compounding pharmacies formulate dapoxetine for individual patients under a licensed prescriber's order, though this carries no FDA efficacy or purity guarantee. Second, daily low-dose paroxetine (10 mg) or sertraline (25 to 50 mg) are FDA-approved SSRIs used off-label for PE with a substantial evidence base, though their daily use introduces a broader side-effect and discontinuation profile compared with on-demand dapoxetine [3].

In the European Union, dapoxetine 30 mg and 60 mg (Priligy, Menarini) is approved and commercially available. In the UK, it is available by prescription after a standardized cardiovascular and psychiatric screening. In Australia, the Therapeutic Goods Administration approved it in 2013. Men traveling internationally should note that importation for personal use is subject to each country's customs regulations.

For US-based telehealth platforms, a prescribing clinician may prescribe off-label paroxetine, sertraline, or tramadol (with appropriate monitoring) while awaiting any future FDA dapoxetine application. Tramadol 25 to 50 mg on-demand has shown IELT improvements in small trials but carries opioid dependence risk and is not a first-line recommendation [3].

The FDA's drug approval database shows no current New Drug Application for dapoxetine under review as of the date this article was reviewed [22].